On Monday, GENinCode PLC (GENI.L), a genetics company specialized in cardiovascular health and ovarian cancer treatment, reported a wider loss in the fiscal year of 2025, despite higher revenue.
On the London Stock Exchange, the shares were trading 13.13 percent down at 0.9990 pence.
Loss before Income tax for the period rose to 5.86 million pounds, from 5.08 million pounds in 2024. The wider loss was attributable to the higher administrative expenses due to increased commercial support and reduced tax credits for research and development.
Loss after tax in 2025 went up to 5.71 million pounds, from 4.43 million pounds in the prior year.
Loss per share went down to 2.08 pence, from 2.53 pence a year ago.
Adjusted EBITDA loss was 4.87 million pounds, compared to the loss of 4.45 million pounds last year.
Revenue for the year 2025 spiked to 3.08 million pounds, from 2.70 million pounds a year ago.
Looking forward to the full year 2026, the company expects higher year-on-year revenues, improved margins and reduced EBITDA losses, while strengthening its commercial, marketing and selling teams to ensure steady revenue growth.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.